top of page
Trans-catheter treatment of ascending aorta aneurysms (TT3A)
TT3A S.r.l. is developing the first on-label structural heart medical device to treat patients with ascending aorta aneurisms. Current surgical treatments of this pathology result in up to an 80% mortality rate. Therefore, our primary objective is to reduce mortality, and hospitalization time.
Complete website coming soon.
External venture of
Contact Antonello Fazio (CEO): firstname.lastname@example.org
About & Subscribe
bottom of page